Fort Lauderdale, Fla., May 31, 2018 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc., a leading global provider of clinical data management technology, today announced the release of TrialMaster Version 5, the innovative, user-friendly solution for electronic data capture (EDC). TrialMaster’s ease of use for investigative sites, coupled with state-of-the-art analytical tools, means that life science companies can shorten the time to market for essential life-saving treatments.
“This is a groundbreaking day for the industry,” said Keith Howells, OmniComm’s chief technology officer. “While the costs for clinical research are climbing inexorably higher, the mechanisms for collecting the precious data have become mired in antiquated, second-rate technology. TrialMaster v5 changes all that. With the product’s ease of use, keystroke-level responsiveness and built-in mobile support, site and sponsor personnel alike will finally have a tool that they feel is on their side. I am confident that TrialMaster v5 would win an evaluation against any of the other EDC products on the market.”
TrialMaster v5 makes it easier for doctors, nurses and other medical professionals to enter and manage clinical trial data, thereby freeing up the maximum amount of time to care for patients. This innovative EDC solution offers:
With an emphasis on a premium user experience, the new TrialMaster EDC represents a major milestone for OmniComm and is part of the company’s “Year of Innovation.” New eClinical solutions from OmniComm include Acuity Analytics, AutoEncoder, IRTMaster and the latest version of TrialOne®. OmniComm will showcase and demonstrate TrialMaster v5 and other new eClinical solutions at industry events around the globe, including Innovation Forum Europe, June 7-8 in Bonn, Germany, and at the DIA 2018 in Boston on June 24-28.
“This release has been close to three years in the making,” said Stephen Johnson, president and CEO of OmniComm. “Significant effort was put into making this the most intuitive and easy-to-use system we’ve ever released, utilizing the latest in cutting-edge technology, HTML5 design, award-winning usability experts, and feedback from a customer steering group. We’ve added features such as liquid layouts, modern controls, infinite scrolling and a host of other techniques to make the user experience the best possible. I have no doubt that this release will revolutionize the way clinical trial data is collected and processed.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.